SCHEMBL362446

SCHEMBL362446

COc1cc(CC=O)c(N)cc1OCCCN1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
CYP2D6 P10635 1/20 0.49
LMNA P02545 2/20 0.48
TDP1 Q9NUW8 3/20 0.46
KDM4E B2RXH2 1/20 0.46
AXL P30530 1/20 0.46
EHMT2 Q96KQ7 3/20 0.45
EHMT1 Q9H9B1 3/20 0.45
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
CHEK1 O14757 1/20 0.44
SYK P43405 1/20 0.44
SRC P12931 3/20 0.43
KDM1A O60341 1/20 0.43
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361838 0.83 CYP2D6 (0.55) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL3284976 0.79 LMNA (0.55) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL362445 0.79 LMNA (0.55) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL5502433 0.79 LMNA (0.55) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL3711173 0.78 LMNA (0.56) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL3471214 0.78 LMNA (0.56) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL13388323 0.77 TSHR (0.51) TSHRCYP2D6LMNATDP1KDM4E
SCHEMBL2163402 0.77 MAP2K1 (0.55) TSHRCYP2D6CHEK1SRC
SCHEMBL3281444 0.77 MAP2K1 (0.55) TSHRCYP2D6CHEK1SRC
SCHEMBL4088385 0.77 SYK (0.59) TSHRCYP2D6CHEK1SYKHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621482-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES Exelixis, Inc. (US) 2013-08-07 EP disclosed
EP-2621483-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES Exelixis, Inc. (US) 2013-08-07 EP disclosed
EP-2593091-A1 C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS Exelixis, Inc. (US) 2013-05-22 EP disclosed
WO-2012044574-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS, INC. (US) 2012-04-05 WO disclosed
WO-2012044577-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS, INC. (US) 2012-04-05 WO disclosed
WO-2012009723-A1 C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS EXELIXIS, INC. (US) 2012-01-19 WO disclosed